An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Hypoxia-inducible factor prolyl hydroxylase inhibitor
chronic kidney disease
hemoglobin
meta-analysis
renal anemia
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
21
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
ppublish
Résumé
Renal anemia, a common complication and threat factor of chronic kidney disease (CKD), has long been treated with injectable erythropoietin-stimulating agents (ESAs). As concerns regarding cardiovascular safety and erythropoietin resistance to ESAs have emerged, alternative therapies are urgently needed. Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), an oral agent, has been proven to be effective in improving renal anemia. However, the effects of HIF-PHIs on nondialysis-dependent CKD (NDD-CKD) have yet to be supported by updated meta-analyses. A meta-analysis of clinical randomized controlled trials (RCTs) on HIF-PHI treatment of NDD-CKD patients based on PubMed, EMBASE, and Cochrane databases as of July 16th, 2023, was conducted. The primary outcomes were the level of hemoglobin (Hb) postintervention and the ratio of Hb responses. Most of the analysis was conducted Twenty-two studies with a total of 7178 subjects in the HIF-PHI group, 3501 subjects in the ESA group and 2533 subjects in the placebo group were enrolled. HIF-PHIs increased the level of Hb and improved iron metabolism but were not inferior to ESAs in terms of safety. HIF-PHIs may be a convenient and safe alternative to ESAs in patients with NDD-CKD and anemia.
Sections du résumé
BACKGROUND
UNASSIGNED
Renal anemia, a common complication and threat factor of chronic kidney disease (CKD), has long been treated with injectable erythropoietin-stimulating agents (ESAs). As concerns regarding cardiovascular safety and erythropoietin resistance to ESAs have emerged, alternative therapies are urgently needed. Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), an oral agent, has been proven to be effective in improving renal anemia. However, the effects of HIF-PHIs on nondialysis-dependent CKD (NDD-CKD) have yet to be supported by updated meta-analyses.
METHODS
UNASSIGNED
A meta-analysis of clinical randomized controlled trials (RCTs) on HIF-PHI treatment of NDD-CKD patients based on PubMed, EMBASE, and Cochrane databases as of July 16th, 2023, was conducted. The primary outcomes were the level of hemoglobin (Hb) postintervention and the ratio of Hb responses. Most of the analysis was conducted
RESULTS
UNASSIGNED
Twenty-two studies with a total of 7178 subjects in the HIF-PHI group, 3501 subjects in the ESA group and 2533 subjects in the placebo group were enrolled. HIF-PHIs increased the level of Hb and improved iron metabolism but were not inferior to ESAs in terms of safety.
CONCLUSIONS
UNASSIGNED
HIF-PHIs may be a convenient and safe alternative to ESAs in patients with NDD-CKD and anemia.
Identifiants
pubmed: 37724564
doi: 10.1080/0886022X.2023.2258986
pmc: PMC10512776
doi:
Substances chimiques
Epoetin Alfa
64FS3BFH5W
Erythropoietin
11096-26-7
Prolyl Hydroxylases
EC 1.14.11.-
Prolyl-Hydroxylase Inhibitors
0
Types de publication
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2258986Références
Nat Rev Nephrol. 2016 Mar;12(3):157-68
pubmed: 26656456
Am J Kidney Dis. 2023 Apr;81(4):434-445.e1
pubmed: 36396085
N Engl J Med. 2006 Nov 16;355(20):2085-98
pubmed: 17108343
Kidney Int. 2021 Jul;100(1):14-16
pubmed: 34154707
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):28-39
pubmed: 30559105
J Am Soc Nephrol. 2012 Oct;23(10):1631-4
pubmed: 22935483
Am J Nephrol. 2017;45(5):380-388
pubmed: 28343225
Blood. 2020 Aug 13;136(7):790-800
pubmed: 31895946
Kidney Int. 2016 Nov;90(5):1115-1122
pubmed: 27650732
Adv Ther. 2019 Jun;36(6):1438-1454
pubmed: 30953333
Am J Kidney Dis. 2018 Mar;71(3):423-435
pubmed: 29336855
Br J Anaesth. 2021 Jul;127(1):e8-e10
pubmed: 33966890
N Engl J Med. 2021 Apr 29;384(17):1589-1600
pubmed: 33913637
Kidney Int Rep. 2021 Apr 17;6(7):1810-1828
pubmed: 34307976
Expert Opin Investig Drugs. 2018 Jul;27(7):613-621
pubmed: 29975110
Adv Ther. 2021 Jan;38(1):52-75
pubmed: 33123967
Am J Nephrol. 2021;52(1):26-35
pubmed: 33561857
Anesthesiology. 2019 Jan;130(1):83-91
pubmed: 30557212
Lancet Haematol. 2021 Aug;8(8):e572-e582
pubmed: 34329578
Kidney Int. 2023 Jun;103(6):1180-1192
pubmed: 36868377
Nephrol Dial Transplant. 2017 Aug 01;32(8):1373-1386
pubmed: 28371815
Int J Mol Sci. 2020 Jan 22;21(3):
pubmed: 31979104
J Am Soc Nephrol. 2021 Mar;32(3):737-755
pubmed: 33568383
Kidney Int Suppl (2011). 2021 Apr;11(1):8-25
pubmed: 33777492
Kidney Int Rep. 2020 Dec 05;6(3):624-635
pubmed: 33732977
Mol Metab. 2020 Nov;41:101039
pubmed: 32534258
Eur J Pharmacol. 2021 Dec 5;912:174583
pubmed: 34678238
Nephrol Dial Transplant. 2021 Aug 27;36(9):1629-1639
pubmed: 33630072
N Engl J Med. 2019 Sep 12;381(11):1001-1010
pubmed: 31340089
Am J Kidney Dis. 2016 Jun;67(6):861-71
pubmed: 26827289
Nephrol Dial Transplant. 2021 Aug 27;36(9):1616-1628
pubmed: 34077510
Am J Nephrol. 2021;52(10-11):884-893
pubmed: 34569482
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Blood. 2020 Aug 13;136(7):783-789
pubmed: 32556307
J Am Soc Nephrol. 2016 Apr;27(4):1234-44
pubmed: 26494831
Kidney Int. 2021 Jul;100(1):79-89
pubmed: 33811979
EMBO J. 2012 May 30;31(11):2448-60
pubmed: 22562152
Am J Nephrol. 2021;52(10-11):894-898
pubmed: 34535582
Am J Nephrol. 2019;49(2):165-174
pubmed: 30699415
JAMA. 2019 Oct 1;322(13):1294-1304
pubmed: 31573641
J Am Soc Nephrol. 2021 Aug;32(8):2020-2030
pubmed: 34244326
Nephrol Dial Transplant. 2015 Oct;30(10):1665-73
pubmed: 26238121
Int Urol Nephrol. 2023 Jan;55(1):167-171
pubmed: 35852713
Am J Nephrol. 2021;52(10-11):871-883
pubmed: 34569489
Clin Kidney J. 2019 Feb;12(1):129-138
pubmed: 30746140
Am J Kidney Dis. 2019 Feb;73(2):206-217
pubmed: 30348535
Nephrol Dial Transplant. 2000 Sep;15(9):1425-30
pubmed: 10978402
Int J Mol Sci. 2018 Jan 29;19(2):
pubmed: 29382128
N Engl J Med. 2021 Dec 16;385(25):2313-2324
pubmed: 34739196
Circ J. 2020 May 25;84(6):1028-1033
pubmed: 32213720